rs4225 — APOC3 APOC3 3'UTR c.*71G>T

APOC3 3'UTR — When a Typo in the Instruction Manual Turns Out to Be Protective

Apolipoprotein C-III (APOC3) is one of the body's most powerful brakes on fat clearance. This small protein, made in the liver and intestine, inhibits lipoprotein lipase and hepatic uptake of triglyceride-rich remnant particles¹¹ inhibits lipoprotein lipase and hepatic uptake of triglyceride-rich remnant particles
the two main mechanisms by which the body clears VLDL and chylomicrons from circulation. When APOC3 levels are high, triglycerides accumulate in the blood; when APOC3 is low, the circulation clears triglyceride-rich lipoproteins efficiently.

The rs4225 variant sits in the 3' untranslated region (3'UTR) of the APOC3 gene — the portion of the mRNA that controls how efficiently the gene's instructions are read but does not itself encode any amino acid. A single nucleotide change (G→T at genomic position chr11:116,832,955 on GRCh38) determines whether a small regulatory RNA molecule called miR-4271²² miR-4271
microRNA-4271, one of ~2,000 microRNAs that fine-tune gene expression by binding mRNA 3'UTR sequences can attach to the APOC3 message and suppress its translation. The T allele creates the binding site; the G allele does not.

The Mechanism

At the molecular level, the T allele at rs4225 base-pairs with a uracil residue in miR-4271 in Watson-Crick mode, while the G allele fails to form this pairing³³ the T allele at rs4225 base-pairs with a uracil residue in miR-4271 in Watson-Crick mode, while the G allele fails to form this pairing
Hu et al. Scientific Reports, 2016, confirmed this using reporter assays and plasma APOC3 measurements. The practical result: people who carry the T allele have lower plasma APOC3 concentrations than G homozygotes (p for trend = 0.03). Lower APOC3 means less inhibition of lipoprotein lipase, more efficient VLDL and chylomicron clearance, and lower circulating triglycerides.

rs4225 is not the only APOC3 3'UTR variant with this mechanism — the nearby [rs5128 (3238C>G) | another 3'UTR variant ~78 bp downstream in the same regulatory region] also modulates miR-4271 binding, and the two variants are in partial linkage disequilibrium. However, rs4225 and rs5128 have independent effects: the T allele at rs4225 is the protective allele (creating the miR binding site), while the G allele at rs5128 is the risk allele (disrupting miR binding). They act on the same pathway but in opposite directional terms.

The Evidence

The foundational study for rs4225 — Hu et al. 2016, Scientific Reports⁴⁴ Hu et al. 2016, Scientific Reports — combined molecular biology (miR-4271 binding assays) with clinical association data in a Chinese case-control population. The T allele associated with decreased triglyceride levels (Beta SE: -0.024, P = 0.03), and the TT genotype produced a modest but statistically significant reduction in overall coronary heart disease risk (OR 0.89, 95% CI 0.77-0.98, P = 0.009) compared with GG homozygotes.

In the larger LURIC study (3,041 participants) and meta-analysis extending to 332,389 participants from CARDIOGRAMplusC4D and UK Biobank⁵⁵ LURIC study (3,041 participants) and meta-analysis extending to 332,389 participants from CARDIOGRAMplusC4D and UK Biobank
Silbernagel et al. Atherosclerosis, 2020, rs4225 was among seven common APOC3 variants confirmed to associate with circulating ApoC-III levels. The G allele raising apoC-III also raised total triglycerides and VLDL-cholesterol significantly, but notably showed no significant association with coronary artery disease across the full meta-analysis (p > 0.1). This apparent paradox — triglycerides up, but no CAD signal — likely reflects that common variants produce modest triglyceride elevation without raising apoB or LDL-cholesterol, unlike the profound lipid changes driven by rare loss-of-function mutations.

The APOC3 loss-of-function literature frames the direction of effect clearly. Crosby et al. (NEJM 2014, 110,970 participants)⁶⁶ Crosby et al. (NEJM 2014, 110,970 participants) showed that LOF mutation carriers have 39% lower triglycerides and a 40% reduction in coronary heart disease (OR 0.60). Jørgensen et al. (NEJM 2014, 75,725 participants)⁷⁷ Jørgensen et al. (NEJM 2014, 75,725 participants) confirmed 44% lower triglycerides and 41% lower ischemic vascular disease risk (HR 0.59). The rs4225 T allele operates on the same axis — less APOC3, lower triglycerides — but with a much smaller effect size, as expected for a common regulatory variant versus a rare protein-disrupting mutation.

Practical Actions

The G allele is the higher-APOC3 allele. GG homozygotes produce the most APOC3 and clear triglycerides least efficiently. Dietary and lifestyle factors that modulate APOC3 expression — omega-3 fatty acids suppress hepatic APOC3 production⁸⁸ omega-3 fatty acids suppress hepatic APOC3 production
through PPAR-alpha activation and transcriptional repression, while refined carbohydrates and saturated fat induce it — have genotype-dependent impact. For GG individuals, reducing dietary inputs that drive APOC3 expression is the most direct lever available.

Regular fasting triglyceride monitoring is meaningful for G carriers. A result above 1.7 mmol/L (150 mg/dL) indicates that the APOC3-mediated impairment of triglyceride clearance is translating into measurable metabolic effect, warranting dietary adjustment.

Interactions

rs4225 is one of several APOC3 variants in the apolipoprotein gene cluster at chromosome 11q23 (APOA1/C3/A4/A5)⁹⁹ apolipoprotein gene cluster at chromosome 11q23 (APOA1/C3/A4/A5)
variants in this cluster interact to set the overall tone of triglyceride metabolism. Related variants rs5128, rs2854116, and rs2854117 operate through overlapping mechanisms. The APOA5 variant rs964184 in the same cluster is a potent independent triglyceride regulator; carrying risk alleles at both APOA5 and APOC3 compounds hypertriglyceridemia risk.

APOE genotype interacts with APOC3 variants. APOE4 carriers already have impaired remnant-particle clearance; adding elevated APOC3 (GG genotype at rs4225) may amplify postprandial triglyceride retention in the same particles.